ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / RNXT / news
BOLD (46) HRTX (34) GOSS (28) NMAD (31) ⌘ Pro Terminal →

Why RNXT Stock dropped -5.26% Today — RQD Quant Desk Flash

$1.26 -5.26% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.25

RenovoRx Inc. (RNXT) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $56.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RNXT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RNXT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, RenovoRx Inc. (NASDAQ: RNXT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.26 (-5.26% 1D, market cap $56.9M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RNXT ranks #840 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RNXT compare to BOLD and HRTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RNXT carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 70.9%, and ROIC of -35.0%. By comparison, BOLD (Boundless Bio Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $56.4M) and HRTX (Heron Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $56.0M). Among the 5-stock peer group, RNXT leads on earnings multiple (N/A) while RNXT leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RNXT?
▼

Per RNXT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001574094), RenovoRx Inc. generated $1.1M in revenue (+2511.6% YoY), -$11.2M in net income, and -$11.0M in free cash flow against $8.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.25 (-1.14%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510029
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (3)Whales (8)SEC (8)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.7% Base Target
$3 Bull$1 Base$1 Bear
📬 FREE RNXT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RNXT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY RNXT SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (28% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)

Altman Z-Score 0.40 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
21
Grade E$1.15+4.3% Next Q
Q2 (-2Q)
24
Grade E$1.20+15.8% Next Q
Q3 (-1Q)
26
Grade E$1.39-9.4% Next Q
Current
29
Grade E$1.26-9.8% Hist 90D α
Trajectory: E (21) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RNXT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RNXT currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.56) and Max Pain ($1.32) forces dealer call-delta covering toward $2.72.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RNXT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RNXT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 29%NO 71%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why RNXT Stock dropped -5.26% Today — RQD Quant Desk Flash

RenovoRx Inc. (RNXT) dropped -5.26% to $1.26, trading at 30% of its 52-week range ($0.7 – $2.59). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 30% of its 52-week range ($0.7 – $2.59) with RSI-14 at 43 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.26 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 70.9% gross margin and $0 annual free cash flow.
Live RNXT Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RNXT)

  • ✓Walkthrough of RNXT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RNXT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +35.48%🛡️ HOLDING TREND SUPPORT
2026-11-04O $1.33H $1.33L $1.26C $1.26VOL 304.3K
RES: $2.07SUP: $1.15SMA50: $1.56SMA200: $1.11
$2.72$2.19$1.66$1.13$0.61RES $2.07SUP $1.15$1.262026-05-052026-06-182026-08-052026-09-182026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RNXT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RNXT Butterfly Map → + Track RNXT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +2511.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RNXT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RNXT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RNXT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RNXT)

Health Care Rank #840 of 1015 ⚔️ BOLD vs RNXT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RNXT vs. BOLD, HRTX, GOSS, NMAD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, RenovoRx Inc. (RNXT) ranks #840 by composite RQD confidence (29/100, grade E) and #719 by equity capitalization ($56.9M). Within this direct 5-issuer industry benchmark cohort, RNXT leads on earnings valuation at N/A trailing P/E, while RNXT leads on capital efficiency and profitability with -35.0% ROIC and 70.9% gross margin. BOLD currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with RNXT at 29/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RNXT ACTIVE
RenovoRx Inc.
E 29/100 — 70.9% -35.0% -5.26% $56.9M Benchmark Subject
BOLD
Boundless Bio Inc.
D 46/100 — — -35.0% -1.22% $56.4M /bold-vs-rnxt →
HRTX
Heron Therapeutics Inc.
E 34/100 — 73.3% -35.0% +6.27% $56.0M /hrtx-vs-rnxt →
GOSS
Gossamer Bio Inc.
E 28/100 — — -35.0% -8.96% $57.8M /goss-vs-rnxt →
NMAD
Nomad Power Solutions Inc.
E 31/100 — — -35.0% -2.53% $55.9M /nmad-vs-rnxt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001574094 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), RenovoRx Inc. (RNXT) reported GAAP revenue of $1.1M (+2511.6% vs. FY2024 revenue of $43.0K , and -96.5% cumulative change since FY2023) , GAAP net income of -$11.2M, operating cash flow of -$11.0M, and free cash flow of -$11.0M (-20.1% YoY). On the balance sheet, RNXT closed FY2025 with $8.1M in total assets against $0 in total debt (Altman Z-Score: 0.40, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.1M -$11.2M -$11.0M -$11.0M $8.1M —
FY2024 (FY) 2024-12-31 $43.0K -$8.8M -$9.1M -$9.1M $8.1M —
FY2023 (FY) 2023-12-31 $31.9M -$10.2M -$10.3M -$10.3M — —

3. RNXT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RNXT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, RenovoRx Inc. (NASDAQ: RNXT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.26 (-5.26% 1D, market cap $56.9M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RNXT ranks #840 in composite RQD confidence.

How does RNXT compare to BOLD and HRTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RNXT carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 70.9%, and ROIC of -35.0%. By comparison, BOLD (Boundless Bio Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $56.4M) and HRTX (Heron Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $56.0M). Among the 5-stock peer group, RNXT leads on earnings multiple (N/A) while RNXT leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RNXT?

Per RNXT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001574094), RenovoRx Inc. generated $1.1M in revenue (+2511.6% YoY), -$11.2M in net income, and -$11.0M in free cash flow against $8.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RNXT trading relative to its 50-day, 200-day, and 52-week technical levels?

RNXT last traded at $1.26 (-5.26% on volume of 304,282 shares), positioning the stock -19.23% below its 50-day simple moving average ($1.56) and +13.51% above its 200-day simple moving average ($1.11). Across its 52-week range of $0.70 to $2.59, RNXT sits at the 29.6% percentile with a 14-day RSI of 43.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.10 to $1.42).

Direct Sub-Reports: RNXT RQD Cockpit RNXT 12M Forecast RNXT Earnings & Move RNXT Dividends & DRIP RNXT Insiders & 13F RNXT Whale Options RNXT Profit Sankey RNXT News & Why
ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ SEC XBRL & RQD VERIFIED

RNXT — RenovoRx Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

RenovoRx Inc. (RNXT) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.26 (-5.26% 1D, market capitalization $56.9M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 70.9%, operating margin of -60.0%, and free cash flow yield of -16.32%.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.40, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. (RNXT) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the recent news wire, the company is associated with a cancer drug-delivery device, with physicians' expanding use of that device referenced as a discussion topic. Revenue was $1.1M in FY 2025 and — in FY 2024 and FY 2023.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), RenovoRx Inc. (RNXT) reported $1.1M in annual revenue (up from $43.0K in FY2024, +2511.6% YoY) and -$11.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($31.9M revenue, -$10.2M net income) through FY2025, RNXT scaled operating cash flow to -$11.0M and free cash flow to -$11.0M, backed by $8.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -16.32% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $0.70 – $2.59 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph records a supply chain status of NONE, with no upstream or downstream links and no sector-correlation signals. Investors should note that the absence of mapped links means the source data cannot identify 2nd-order bottlenecks; any dependency analysis would require information not present here.

  • Key Question #1: Can RNXT sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.1M and free cash flow of -$11.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is RNXT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

RNXT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for RenovoRx Inc. (RNXT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RNXT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RNXT Bull vs. Bear Conversation Board — What's Your Call at $1.26?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RNXT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RNXT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $1.64 (+23.3%)
📌 Pinned Debate

Institutional accumulation and options positioning (11 of 20 on the Whale 13F Flow pillar) is the strongest pillar in an otherwise weak

The street is overcomplicating RenovoRx Inc. (RNXT). Institutional accumulation and options positioning (11 of 20 on the Whale 13F Flow pillar) is the strongest pillar in an otherwise weak RQD profile.. With an RQD score of 29/100 (E) and Forensic Balance Sheet at 8/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.44.

CapAlloc_Nerd 🐂 BULL

@MacroHawk_NYC Agree on the RQD 29/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.33 and keeping dry powder in case we test $1.24.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $1.01 (-24.1%)
Spot @ $1.33

Persistent negative free cash flow of -$11.0M in FY 2025 against an Altman Z of 0.4 and a -35% ROIC points to forensic balance-sheet an

Sitting on the sidelines or leaning short RNXT above $1.33. Persistent negative free cash flow of -$11.0M in FY 2025 against an Altman Z of 0.4 and a -35% ROIC points to forensic balance-sheet and cash-engine risk.. Until Fundamental Cash Engine (3/20) and FCF yield (-16.32%) inflect higher, upside is capped near $2.59.

LIVE TAPE